Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi (SNY) CEO Paul Hudson on Q3 2019 Results - Earnings Call Transcript

Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.

Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales

Sanofi's (SNY) Specialty Care and Vaccines units are likely to have driven third- quarter earnings.

Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?

Sanofi SNY, -0.80% SAN, -1.08% announced Friday a recall of over-the-counter heartburn medication Zantac in the U.S.

Sanofi recalls Zantac because of possible contamination with potentially cancer-causing NDMA

Zantac, whose generic versions are known chemically as ranitidine, is the latest drug in which cancer-causing impurities have been found.

Sanofi to pull heartburn drug Zantac in US, Canada

Greenbrier Companies

Green Dot

Summit Hotel Properties

EnPro Industries

Pampa Energia

A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.

7 Value Price-to-Sales Stocks Poised to Fetch Strong Gains

Sanofi SA's (NASDAQ:SNY) newly minted CEO is looking under the hood to figure out what’s needed to get the company in gear.

New Sanofi CEO Looks to Shake Things Up

Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late

Sanofi (SNY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Sanofi

Regeneron Pharmaceuticals

Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.

Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent

Sanofi (SNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sanofi (SNY) Soars to 52-Week High, Time to Cash Out?

AbbVie

Gilead Sciences

Eli Lilly

Novo Nordisk

Patents and monopolies don’t always go hand in hand.

An Investor's Guide to Disrupting Drugmakers

Abbott Labs

Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.

Abbott Partners With Sanofi to Upgrade Diabetes Management

A commonly used heartburn medicine from Sanofi, known as Zantac, could contain cancer-causing substances, the Food and Drug Administration said Friday. But Sanofi stock rose a fraction.

Popular Sanofi Heartburn Drug Could Contain Carcinogens, FDA Says

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc.’s (NASDAQ: LXRX) shares made a huge gain on Wednesday after the announcement that its alliance with Sanofi (NASDAQ: SNY) was terminated.

What’s Left After Lexicon’s Terminated Partnership With Sanofi

Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.

Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally

Regeneron (REGN) and partner Sanofi get a favorable ruling against Amgen in the ongoing litigation of Praluent.

Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court

Amgen

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc  patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc  and Sanofi SA , which sells a rival drug.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

Sanofi reported a substantial revenue boost, but non-recurring items had a negative impact on net income.

Sanofi: Look Through The Impairment Charges To See The True Underlying Value

Assessing An Investment In Sanofi

Dick's Sporting Goods

Realty Income Corp

Sanofi, Realty Income, and Dick's Sporting Goods might just serve up more refreshing returns than the beverage giant.

3 Dividend Stocks  That Pay You More Than Pepsi Does.

Pfizer

SNY vs. PFE: Which Stock Is the Better Value Option?

Sanofi S.A. (SNY) CEO Olivier Brandicourt on Q2 2019 Results - Earnings Call Transcript

Sanofi (SNY) beats estimates for second-quarter earnings. Key immunology drug Dupixent drives sales.

Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up

Sanofi (NYSE: SNY) shares are trading higher after the company reported better-than-expected second-quarter earnings.

News for Sanofi Stock (SNY)